ReviewCurrent gastroenterology reports2014
The pharmacologic treatment of short bowel syndrome: new tricks and novel agents.
Review in Current gastroenterology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 34 citations in OpenAlex.
- Enhancing drug therapy in ostomy patients: Best practice recommendations for medication management.PloS one · 2024Article
- State of the Art Bowel Management for Pediatric Colorectal Problems: Hirschsprung Disease.Children (Basel, Switzerland) · 2023Review
- Evaluation and Management of Persistent Problems After Surgery for Hirschsprung Disease in a Child.Current gastroenterology reports · 2021Review
- Severe Intestinal Dysbiosis in Rat Models of Short Bowel Syndrome with Ileocecal Resection.Digestive diseases and sciences · 2020Article
- Controversy in Nutrition Recommendations for Short Bowel Syndrome: How Type of SBS Impacts Response.Current gastroenterology reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Short bowel syndrome (SBS) is a manifestation of massive resection of the intestines resulting in severe fluid, electrolyte, and vitamin/mineral deficiencies. Diet and parenteral nutrition play a large role in the management of SBS; however, pharmacologic options are becoming more readily available. These pharmacologic agents focus on reducing secretions and stimulating intestinal adaptation. The choice of medication is highly dependent on the patient's symptoms, remaining anatomy, and risk versus benefit profile for each agent. This article focuses on common and novel pharmacologic medications used in SBS, including expert advice on their indications and use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.